Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARK Space & Defense Innovation ETF (ARKX) vs Novartis AG (NVS) Price & Performance

ARK Space & Defense Innovation ETFTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

ARK Space & Defense Innovation ETF vs Novartis AG — how do they compare? ARK Space & Defense Innovation ETF trades at $34.45, while Novartis AG trades at $152.59 (market cap $295.37B). The key difference: Novartis AG pays a 3.07% dividend while ARK Space & Defense Innovation ETF pays none. Which is the better fit depends on your goals.

ARKXNVS
Sector
Sector/ThematicHealth
52-Week High
$37.74$168.62
52-Week Low
$25.46$119.31
Market Cap
$295.37B
Enterprise Value
$336.69B
Dividend Yield
3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARK Space & Defense Innovation ETF

No Aura AI signal available yet.

Novartis AG

Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.

The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ARK Space & Defense Innovation ETF

ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.

Read more on ARKX

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS